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ABSTRACT
Jun/Fos and Jun/BATF heterodimers are capable of binding the TRE site to regulate gene
transcription, which in turn amongst other functions, could be involved in the regulation of
inflammation. Studies have shown that in contrast to Jun/Fos, the Jun/BATF heterodimers result
in a reduced transcriptional activity and thus inhibit the expression of AP-1 target genes.
The inflammatory response is composed of a vast array of mediators, including cytokines such as
IL6 and IL10. The balance between pro-inflammatory and anti-inflammatory mediators, in part,
determines whether the inflammatory response persists or is resolved. Macrophages are a key
cell type involved in the inflammatory response.
The goal of this research was to determine the expression of BATF in comparison to Fos
expression when M1 cells were stimulated with the known inflammatory triggers, IL6, IL10 and
LPS. Although M1 cells do not express c-Fos, they do express Fra-1, which is also a member of
the Fos family.
Stimulation of M1 cells with IL6, IL10 and LPS resulted in co-expression of BATF and
Fra-1 as a result of stimulation with each inflammatory trigger. Further studies will be required to
measure transcription factor binding to an AP-1 consensus DNA sequence. This would give more
conclusive evidence as to which of the two dimers Jun/BATF or Jun/Fos is actually binding and
thus giving rise to the control of the TRE site following the stimulations. This would also show
whether the transcription factor that was predominantly expressed produced its effect through the
TRE site or whether on the contrary, BATF and Fra-1 were coexpressed and had different
promoter targets.
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CHAPTER 1
LITERATURE REVIEW

OVERVIEW OF THE ROLE OF MACROPHAGES IN INFLAMMATION:
Macrophages are continually responding to injury, infection, trauma and many other
insults from the environment (1, 2, 3). The ability to respond to these stimuli makes them key
players in the maintenance of tissue homeostasis. If macrophages are unable to reestablish
tissue homeostasis alone, they mobilize and orchestrate other cellular systems to restore normal
function. The inflammatory response is an example of a reaction brought about by the
macrophages in response to environmental changes (1, 3).
Inflammation is a vital response and an integral function of the body’s immune system.
This response, which includes both localized and systemic effects, consists of altered patterns of
blood flow, an influx of phagocytic and other immune cells, production of a series of tissue
mediators, removal of foreign antigens and healing of the damaged tissue (4, 5, 6).
Macrophages have a class of receptors known as toll-like receptors (TLRs), which
recognize a given class of molecules that are unique to microorganisms (5, 7, 8, 9). The
recognition of these bacterial molecules by the TLRs is known as pattern recognition and it is a
part of innate immunity. Through these TLRs the macrophage is able to detect the presence of
bacteria. For example TLR4 recognizes the presence of lipopolysaccharide (LPS), the major
glycolipid on the outer membrane of Gram negative bacteria. Engagement of TLR4 elicits
activation of the TLR4 signaling pathway and results in the production of a series of inflammatory
mediators in the macrophages such as lysosomal enzymes, cytokines, reactive oxygen species,
prostaglandins and nitric oxide. The lysosomal enzymes, activated oxygen species and nitric
oxide all function in killing of the microbe during phagocytosis (3). Once phagocytosis has taken
place, the antigen is then processed and presented. Macrophages present specific bacterial
antigens to effector T cells on site to carry on adaptive immunity.(5, 8).
The inflammatory mediators produced by macrophages are important, amongst other
functions, for the recruitment of other cell types such as neutrophils to help with the response (5,
6,10). During the inflammatory response, this integration of innate and adaptive immunity results
in the elimination of the invading organism.

INFLAMMATION:
The term inflammation largely describes the vascular events that cause the ‘cardinal
signs’ of inflammation. These signs are: Redness due to vasodilation that increases blood flow
to the site of inflammation; swelling due to changes in vascular permeability that allows leakage
of fluid into the tissues; heat because increased blood flow to the site of infection increases local
temperature; pain due to mediators produced at the site of inflammation that sensitize nerve
endings (3,4,5,6). A variety of tissue mediators are produced during the inflammatory response
and these function in perpetuating this response (2). These mediators are released by cells
damaged from tissue injury, produced by the invading microorganisms, or are products of the
white blood cells that participate in the inflammatory response. The mediators that cause the
vasodilation are prostaglandins and nitric oxide.

Increase in vascular permeability is brought

about by vasoactive amines, bradykinin, leukotrienes C4, D4 and E4 and platelet-activating
factor acting on the endothelial cells. Chemotaxis and leukocyte activation are a result of
bacterial products, leukotriene B4, C5a, and cytokines such as IL-1, IL-6, TNF-a and
prostaglandins acting systemically to induce fever during the response. The pain is brought
about by prostaglandins and bradykinin sensitizing nerve endings. In addition to the tissue
damage from the microbe itself, the mediators also cause tissue damage when released
prematurely by overactive phagocytic cells (4, 5, 6).
Acute inflammation is short term, usually lasting a couple of hours to a few days,
depending on the degree of insult. It is beneficial to the body in the sense that during acute
inflammation, cells are recruited to deal with an infection or a foreign body. Once the infection or
foreign body is cleared, the inflammatory response subsides. However, inflammation may act as
a double-edged sword because an excessive and prolonged response can cause tissue
damage, contributing to the pathogenesis of many disease states. This prolonged response,
usually lasting weeks to months to years, is chronic inflammation that occurs when the acute
response cannot be resolved. This is either because of persistence of the injurious agent or
because of interference in the normal process of healing. Changes that occur during chronic
inflammation often lead to more harm than good. Macrophages are central to the inflammatory

response because they secrete cytokines that are crucial for triggering the inflammatory
response and they also respond to cytokines via receptors on their surfaces (2, 3, 4). These
receptors make them capable of responding to many different cytokines and thus control a
myriad of responses in the body (Table 1, p31).
Cytokines are a class of proteins that act as intercellular signals to integrate and control
those cells involved in immune responses. Cytokines are produced principally by activated
macrophages and leukocytes. They can have autocrine, paracrine or endocrine effects. They
may also act on multiple target cell types (pleiotropy). Cytokines have no inherent activity; their
biological actions are dependent on the expression of their cognate receptors on the target cells
(5, 6, 10). Cytokine receptors are expressed on many different cell types and these receptors are
structurally diverse.

THE MACROPHAGE RESPONSE:
Macrophage surface receptors regulate different activities such as inflammation because
the type of response obtained from their activation is dependent on the cytokine that bound to
the cytokine receptor on the macrophage and the corresponding signaling pathway that was
triggered (1, 5, 10). The type of response obtained is dependent on the cytokine that engaged
the receptor in the first place. Activation of the macrophages by the binding of the different
cytokines results in the transcription of genes for the production of various secretory products
including enzymes, complement components, coagulation factors, cytokines and other mediators
(1 ,1 0 ,1 1 ) (Table 2).
The cytokines secreted by macrophages recruit and activate other cells to carry on the
inflammation. The macrophage response therefore must be under strict control in order to avoid
the pathological effects of many chronic inflammatory disease states. (5).
The inflammatory response is composed of an elaborate cascade of inflammatory
mediators. As with other tissue homeostatic responses, the immune response has built in
mechanisms to counteract the inflammatory response. This ensures that the response is
sufficient to clear the insult but does not cause excessive harm to the body. When macrophages
first respond to an insult, the response produces inflammation and as the insult is cleared, the

healing process begins. In contrast, the persistence of an insult causes continued tissue
destruction, inflammation, repair and healing. Both pro-inflammatory and anti-inflammatory
mediators are produced and the inflammatory response persists and intensifies (i.e. becomes
chronic), instead of being limited and leading to resolution (1, 2, 3, 12).
CHRONIC INFLAMMATION:
Chronic inflammation usually occurs as a progression from acute inflammation or after
repeated episodes of acute inflammation. Microorganisms such as Mycobacteria tuberculosis (M.
tuberculosis), Actinomycetes, and numerous fungi including Cryptococcus neoformans, protozoa
and metazoal parasites induce chronic inflammation by possessing mechanisms for resisting or
evading the immune response. Such organisms are either able to avoid phagocytosis or survive
within phagocytic cells. M. tuberculosis is able to survive within the macrophage phagosome after
phagocytosis and thus presents a continuous activation of the macrophage, resulting in chronic
inflammation (1, 13).
When bacteria are phagocytosed, they are taken up into the endosomal system of the
cell where two processes should take place. Normally, the bacteria are first killed and then the
bacterial peptides are presented on Major Histocompatibility Complex II (MHO II) proteins in order
to stimulate a humoral response to the bacteria (5). Macrophages present these peptides to T
helper cells that become primed after recognition of the processed antigen. However it has been
shown that M. tuberculosis inhibits MHO II expression on infected phagocytes. This disrupts the
sequence of events of antigen presentation and thus these organisms survive. It has also been
shown that M. tuberculosis inhibits phagosome-lysosome fusion. Mycobacteria may act from
within the macrophage phagosomes to prevent phagolysosome formation and thus avoid the
lysosomal hydrolases. The infected macrophage (normally in the lung alveoli) also produces
chemokines that attract monocytes and neutrophils.

However none of these cells are able to

effectively kill the M. tuberculosis due to its intracellular location. The mycobacteria are not killed
but instead persist, resulting in the continual macrophage activation. Persistence of the causative
stimulus to inflammation in the tissue leads to the classic tuberculosis granuloma. These are
tumor-like masses that contain many activated macrophages, T helper cells and multinucleated

giant cells formed by the fusion of macrophages. This "contained" form of tuberculosis is
characterized by low numbers of infecting mycobacteria but high levels of inflammation (13, 14).
Chronic inflammation also occurs in a number of autoimmune diseases such as in
systemic lupus erythematosis (SLE) and rheumatoid arthritis. In these conditions, the disease
process is initiated by an insult that damages tissues and is then maintained because of an
abnormality in the regulation of the body's immune response to its own tissues. This results in a
self-perpetuating immune reaction because the antigens causing the response are self proteins
and therefore persist (5). The etiology of rheumatoid arthritis is unknown but the pathogenesis of
rheumatoid arthritis is based on pathophysiological and experimental evidence that shows an
exogenous or self-antigen enters the synovium and is presented to CD4+ T cells. A cascade of
events follow, that result in a highly activated inflammatory environment. A wide range of
inflammatory mediators, including cytokines and their inhibitors, are produced in abundance. The
synovial membrane overgrows and begins to invade the articular cartilage as large numbers of
macrophages, as well as other cartilage cells at the synovium-cartilage interface secrete matrixdegrading proteolytic enzymes. The macrophages also secrete inflammatory cytokines. These
interlinking events result in the synovial inflammation. The degree of joint damage that follows
depends on the intensity of the inflammation (5,15).
Prolonged exposure to exogenous non-degradable toxic agents such as particulate silica
can also induce a chronic inflammatory response in the lungs, leading to silicosis. In the normal
lung, defense functions are mediated by epithelial cells of the airways and alveolar regions,
resident alveolar macrophages and numerous proteins in the extracellular spaces. The epithelial
cells provide a mechanical barrier that retards the entry of foreign substances. Mucous entraps
the exogenous substances. The cilia on the epithelial cells help propel the exogenous substances
out of the body (3, 4). Resident lung macrophage provide lung defense by phagocytosis of foreign
particles and secretion of cytokines (16). In the presence of persistent exogenous substances,
infiltration of phagocytes, specific immunologic mechanisms, such as antibody production by B
lymphocytes and cellular cytotoxic actions by T-lymphocytes augment the primary defense
functions. Inflammatory cells recruited into the lungs tend to produce indiscriminate injury to

resident lung cells and tissues by non-selective release of proteases, oxygen free radicals, and
other cytotoxic agents. This non-selective release of mediators is due to the premature release of
proteases from overactive macrophage lysosomes. This results in a chronic inflammatory state
as the exogenous substance such as silica, which is non- degradable, cannot be readily cleared.
In these conditions, accumulation and activation of macrophages is the hallmark of chronic
inflammation (17).
Apart from chronic inflammation in itself being a problem, as shown in the previous
examples, chronic inflammation can give rise to other problems such as the development of
cancer. A substantial body of evidence supports the suggestion that chronic inflammation can
predispose an individual to cancer (18, 19, 20), as demonstrated by the association between
chronic inflammatory bowel diseases and the increased risk of colon carcinoma. A study by
Bernstein et al. examined the incidence of colon cancer among persons with inflammatory bowel
disease (IBD) compared with those of a non-IBD population. The longer the inflammation
persisted, the higher the risk of dysplasia, which was then followed by carcinogenesis. (21). The
fact that chronic inflammation impacts crucial cellular processes such as proliferation, adhesion,
apoptosis and transformation highlights its pivotal role in the pathogenesis of malignancy.
These examples give an indication of the role played by chronic inflammation in the
pathogenesis of different diseases. An understanding of the regulation of the inflammatory
response will contribute greatly towards progress in the management and treatment of these
diseases.
TRANSCRIPTIONAL REGULATION OF THE INFLAMMATORY RESPONSE:
Evidence suggests that the inflammatory response initiated by the pro-inflammatory
cytokines produced by macrophages is counterbalanced by anti-inflammatory cytokines that turn
off the process when the pathogen or primary cause is eliminated (6,12). Because macrophages
are key amplifiers of the inflammatory response, it is important that these cells are tightly
regulated. The macrophage response to changes in the environment is largely controlled by the
regulation of gene expression. Transcription factors are regulatory proteins capable of binding
directly to DNA sequences and mediating the binding of RNA polymerase for the initiation of

transcription; they can either stimulate or repress transcription of a gene. These transcription
factors therefore play a role in converting extra-cellular signals into changes in the expression of
specific

genes

and

thereby regulate

complex

biological

processes

(11).

Furthermore,

transcriptional activity represents an integration of all the signals coming from the macrophage’s
environment to generate an appropriate response.
When a macrophage is activated through the binding of a cytokine to its receptor, a
series of intracellular events leads to the transcriptional activation of specific genes. This means
that transcription factors bind to the regulatory region (promoter) of a gene and this allows the
gene product to be expressed. Transcriptional regulation of eukaryotic genes often requires the
cooperative or antagonistic action of several proteins. These proteins translocate into the nucleus
and function either individually or cooperatively in regulating the expression of target genes. The
type of response obtained from the activation is dependent upon which cytokine receptors are
engaged, other signals acting on the macrophage and the resulting combination of transcription
factors activated in the nucleus of the macrophage (11). Likewise, the resolution of inflammation
requires specific signaling events (1). Inflammation can be turned off in a number of ways such as
by the degradation of transcription factors, inactivation of the transcription factors by processes
such as dephosphorylation, or modulation of proteins required for transcription factor regulation
(11).

Most advances in the understanding of the contribution of transcription factors in
macrophages have focused on the induction of the inflammatory response rather than its
resolution. An example of a well-studied transcription factor that is activated during the
inflammatory response is the transcription factor activator protein 1 (AP-1). It was initially
described as a heterodimer of c-Jun and c-Fos that binds to the 5 -TGAGTCA-3' motif known as
the TPA (PMA)-responsive element (TRE) (22,23). However, current views suggest that AP-1
represents a family of distinct homodimers or heterodimers composed of various members of the
Fos, Jun and ATF basic leucine zipper family (24, 25) (see figure 1).
Members of the leucine zipper family include c-Jun, JunB, JunD, c-Fos, Fos-B, Fra-1,
Fra-2, ATF-2, ATF-a and ATF-3 (24, 26). The leucine zipper motif is an alpha helix of 30-40

amino acid residues that contains a leucine every seven amino acids, positioned so that they
align on the same side of the helix. Two helices dimerize so that the leucines of one helix align
with the other helix through hydrophobic interactions to form a coiled coil. The portion of the dimer
known as the DNA binding domain (DBD), adjacent to the zipper, interacts with the DNA through
basic amino acid residues (arginine and lysine) that bind to the negatively charged phosphate
groups of the DNA (11, 24, 26, 27).
Several homologues of c-Jun (JunB and JunD) and c-Fos (Fos-B, Fra1 and Fra2) have
also been shown to form heterodimers. Fos/Jun heterodimers have a higher affinity for DNA
binding than Jun homodimers. Enhanced DNA binding activity of the Fos/Jun heterodimer
compared to Jun homodimers can be explained by the rate of association and dissociation from
the TRE and/or by the stability of protein molecules in the dimeric state. Jun homodimer
dissociates very rapidly from the DNA while the off-rate of the Fos/Jun heterodimer is
considerably slower, reflecting its higher affinity (27, 28).

In addition, members of the activating

transcription factor (ATF) family, such as BATF, ATF-2, ATF-3 and ATF-4, can interact with
members of the Fos and Jun family of proteins. Whereas Jun and some ATF proteins form stable
homodimers as well as heterodimers, c-Fos is incapable of binding DNA as a homodimer.
Therefore c-Fos exhibits no biological activity as a homodimer. BATF forms heterodimers with
Jun that bind to consensus ATF/AP-1 DNA sites (29). BATF does not form homodimers, nor does
it form heterodimers with Fos or with other bZIP proteins (26).
AP-1 is activated in response to a diverse range of stimuli. Many genes have AP-1 sites
in their promoters. Thus AP-1 is involved in the regulation of a large number of genes. Although
the core sequences of the AP-1 binding sites show a high degree of homology, the variation in
these binding sites suggests that different AP-1 complexes may bind with varying affinities and
differentially affect transcription of specific target genes. To understand the biological functions of
AP-1, it is important to elucidate the roles that individual basic leucine zipper proteins play in the
cell as part of the AP-1 complexes. For example, the Fos/ Jun heterodimers bind with high affinity
to the sequence motif 5'-TGAGTCA-3'. A c-Jun/ATF2 heterodimer shows low binding activity to
the same motif, however, this heterodimer binds with high affinity to the sequence 5 -

TTACCTCA-3' found in the c-Jun promoter. Thus different DNA sequence elements are
preferentially recognized depending on the composition of the AP-1 dimer.
Basic leucine zipper family proteins are common regulators of gene expression in a
variety of tissues and cell types (24, 26, 27, 28). A bZip protein found mostly in hematopoietic
tissue is BATF. We were particularly interested in this protein because it appears to be involved in
the negative regulation of the responses mediated by Fos/Jun. The first isolation of BATF was
from a cDNA library prepared from human B cells which had been infected with the Epstein-Barr
virus (EBV, 30, 31 ). Analysis of other human tissues and cell lines revealed expression of the
940-base BATF mRNA predominantly in tissues of hematopoietic origin, (30) with constitutive
expression in T lymphocytes and inducible expression demonstrated in B lymphocytes from
peripheral blood (32). Flowever the highest level of BATF was detected in an EBV-positive human
B-cell line known as Raji, which is a cell line derived from Burkitt’s lymphoma. EBV-negative
human B cells from peripheral blood do not express BATF until infected with biologically active
EBV. Studies demonstrate that within 24 hours of infecting human B cells with biologically active
EBV, BATF mRNA is induced 25-fold, suggesting that the induction of BATF mRNA and protein is
an early cellular response to the virus (30). It is also known that EBV and HTLV-1, human viruses
associated with long periods of latency, upregulate the expression of BATF in cells. It is possible
that these viruses induce BATF in the cell to regulate gene expression required for latency (30,
32).
BATF is able to form dimers with members of the Jun transcription factor family to bind to
AP-1 promoter sites in the DNA to carry out its regulatory activity. Studies have also shown that
the BATF/Jun heterodimers result in a decreased transcriptional activity of the target gene, thus
inhibiting the expression of the AP-1-regulated protein (32, 33). This is in contrast to Fos/Jun
heterodimers. Thus Fos/Jun promotes the transcription of certain genes and BATF/Jun prevents
transcription of those same genes (26, 32) (Figure 2).

This suggests that the major cellular function of BATF is as a negative regulator of AP-1
mediated transcriptional events. This is of particular interest to us because it could suggest a
possible role for BATF during inflammation, especially given that its expression is specific to
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hematopoietic tissue. Fos has been shown to be a key transcription factor involved in the
inflammatory response, and the question becomes “Is BATF a key transcription factor involved in
the resolution of inflammation?” The goal of this research was to explore the timeline of
expression of BATF and Fos in response to LPS and to the cytokines IL-10 and IL-6.

As

mentioned, LPS is the major glycolipid on the outer membrane of gram-negative bacteria.
Activation of macrophages by LPS is known to result in production of cytokines necessary for the
inflammatory response via the MAP kinase and NF-kB pathways (5, 40). Both pathways lead to
upregulation of AP-1 mediated responses. IL-10 has been shown to be a major anti-inflammatory
cytokine. Engagement of IL-10 or IL-6 receptors on macrophages activates the STAT-3 pathway
and STAT-3 has been shown to induce BATF expression. (5, 12, 35, 36, 37). IL-6 also activates
the MAP kinase pathway via an SHP-2 domain. SHP-2 transmits signals to the Ras pathway
through Grb2/Sos and/or Gab1/Gab2, resulting in the activation of ERK MAP kinases. Below is a
discussion of the signaling pathways of the stimuli that are of relevance to this research.

TLR-4 PATHWAY:

The TLR-4 pathway is relevant to this research because cells respond to the presence of
LPS through this pathway. LPS is a known stimulant of inflammation. (3, 4, 5) Toll-like receptors
(TLRs) are the principal signaling molecules through which the innate immune system senses
infection and the endpoint of this signaling pathway is the production of cytokines. TLRs are
therefore an important link between the mammalian host and the microbe by making the host
aware that pathogens are present. TLRs are classified into ten categories based on the types of
microbial products they recognize (38). Each TLR recognizes a unique set of molecules produced
by microbes, known as pathogen-associated molecular patterns (PAMPs). Macrophages respond
to the presence of LPS via TLR4 by producing pro-inflammatory cytokines (i.e. IL-1, TNF-a and
IL-6), bioactive lipids (such as prostaglandins) and reactive oxygen species. LPS is therefore proinflammatory in nature. Once TLR4 is engaged, the LPS/TLR4 complex undergoes a
conformational change that is sensed in the cytoplasmic compartment (see figure 3). This
mediates the recruitment of MyDSB to the Toll-IL-1 resistance (TIR) domain of the LPS/TLR4
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complex (40). The recruitment of MyD88 to the proximal TIR allows for the interaction with the IL1R-associated kinase (IRAK) family members. IRAK is then auto-phosphorylated and ieaves the
receptor complex to interact with TNF receptor associated factor (TRAF)-6. The subsequent
activation of (TRAF)-6 results in two signaling pathways becoming activated i.e. NF-kB pathway
and the MAP kinase pathway. The MAP kinase pathway, also known as the extracellular-signal
regulated protein kinases (ERKs) is a signaling pathway that responds to extracelluiar signals
such as cytokines, growth factors and stress which terminate in a three MAP kinase enzyme
cascade. In this cascade, each enzyme phosphorylates the next, thereby activating it (7, 38, 40,
41,42).

In the LPS induced MAP kinase pathway, (MEKK-1) MAPK kinase kinase 1 is activated
by TRAF-6 via the protein adaptor molecule ECSIT. MEKK-1 in turn activates MEKK-4, which
results in the phosphorylation and activation of Jun kinase (JNK). JNK then activates the
transcription factor AP-1 via phosphorylation of Jun. 12-0-tetradecanoyl phorbol-13-acetate
(TPA) is known to upregulate both Fos and Jun through the MAP kinase pathway, and this could
possibly mean that LPS acts on Fos and Jun in the same manner because it uses the same
pathway as TPA (38).

Recruitment of the adapter TRAF6 also leads to the activation of the inhibitory kappa B
(I k B) kinase (IKK) complex. The kinase then phosphoryiates I k B. Phosphorylation of Ik B results in

its release from the N F k B dimer. N F k B then translocates into the nucleus, where it activates
genes encoding inflammatory proteins such as IL6 (41, 42). There is no known direct effect of
NFkB on Fos or BATF. However, it has been shown that at the transcription level NFkB interacts
with Fos/Jun synergistically, leading to greater inflammation than would be present if either NFkB
or Fos/Jun were activated alone (42).

IL-6 AND IL10 PATHWAYS:
IL-6 and IL-10 were relevant to this research because the presence of these cytokines
results in the activation of STAT-3. STAT-3 activation is also known to result in an increase in
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BATF (34). Studies by Gao et al. (43) show that in animal models of sepsis, STAT-3 is the most
important mediator of anti-inflammatory signals in macrophages. In fact the loss of STAT-3 in
hematopoietic-specific knockout mice resulted in progressive inflammatory bowel disease (43).
Given the above information, we decided to explore what effect stimulation of M1 cells with
either IL-10 or IL-6 would have on the levels of expression of BATF and Fos.
INTERLEUKIN-6
Macrophages express IL-6 receptors on their cell membranes (1, 5) and consequently
are capable of responding to the cytokine IL-6. The IL-6 receptor belongs to the Class I cytokine
receptor family, also known as the hematopoietin receptor family. In addition to being a member
of the class I family, the IL-6 receptor belongs in the IL-6 receptor subfamily. IL-6, IL-11,
Leukemia Inhibitory Factor (LIF), Oncostatin M (GSM) and ciliary neurotrophic factor (CNTF)
receptors belong to this subfamily (5).
This subfamily is characterized by receptors that have glycoprotein 130 (gp130) as a
common signal transducing subunit. The IL-6 receptor is composed of two different subunits, an
alpha subunit (IL-6R») and gp130. The alpha subunit provides ligand specificity and the
glycoprotein is the signal transducing subunit (5, 44, 45). IL-6 uses tyrosine kinases of the JAK
family and transcription factors of the STAT family as major mediators of signal transduction.
The signal is initiated when IL-6 interacts with two independent ligand binding alpha subunits.
Once IL-6 engages these subunits, a series of intracellular events are initiated (see figure 4).
Receptor engagement induces dimerization of gp130 with another gp130 subunit
(homodimerization) and signaling is triggered. Homodimerization of gp130 leads to gp130associated Janus kinase (JAK) activation i.e. JAK1, JAK2, or tyrosine kinase 2 (Tyk2). Activation
of these kinases results in the phosphorylation of the cytoplasmic tail of gp130. Several
phosphotyrosine residues of gp130 are docking sites for STAT factors (mainly STAT-1 and
STAT-3) via their SH2 domains. SH2 domains are responsible for the binding of the STATs to
the tyrosine-phoshorylated receptor motifs and also for homodimerization or heterodimerization
with other tyrosine phosphorylated STATs. Activated JAK kinases phosphorylate and activate
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STAT transcription factors, particularly STAT-3 and SHP2 (Src Homology-2 Domain-containing
Tyrosine Phosphatase). Phosphorylated STATs then form dimers and translocate into the
nucleus where they regulate transcription of STAT target genes by binding to Interferon
regulatory factor response element (IRE) motifs in the associated promoter. SHP2 is a tyrosine
phosphatase that contains two SH2 domains. Upon binding to a phosphotyrosine motif, the
phosphatase becomes activated and might be involved in dephosphorylation of Jaks and their
associated receptors. This would be important for inhibiting the continual activation of the STATs
and thus would be Important in down regulating the response they produce. Moreover, SHP2
acts as an adapter protein that links gp130 to the mitogen-activated protein kinase (MAPK)
pathway, which is also activated upon IL-6 stimulation (44, 45, 46).
The cytokine IL-6 is produced by macrophages and endothelial cells (5). IL-6 Is a key
mediator of inflammation because it is involved in inducing the systemic effects of inflammation,
collectively known as the acute phase reaction. IL-6 stimulates the hepatic synthesis of acute
phase proteins; it influences adaptive immunity (proliferation and antibody secretion by the B cell
lineage); it stimulates T cell proliferation and differentiation into cytotoxic T effector cells. In
addition, IL-6 is pyrogenic, increases vascular permeability, and increases intracellular pH. IL-6
also acts on the bone marrow stem cells, stimulating the monocyte precursor cells to proliferate
(1), thus producing monocytes that can migrate into tissues to become macrophages when
needed.
INTERLEUKIN-10
IL-10 is also important in macrophage function. Interleukin-10 (IL-10) activates a diverse
array of functional responses in mononuclear phagocytes. It is secreted by macrophages and by
activated T and B cells and serves to inhibit production of many pro-inflammatory cytokines such
as IL-1, IL-6, IL-8, IL-12, GM-CSF, G-CSF, M-CSF, TNF, NF, MIP, MIP-2 and RANTES. IL-10 is
therefore considered as the primary anti-inflammatory cytokine of the immune system because it
inhibits the production of many other inflammatory mediators (1, 5, 35).
IL-10 synthesis usually occurs during the inflammatory response. If IL-10 is neutralized,
the inflammatory condition usually exacerbates. IL-10 has therefore been suggested as a
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possible therapeutic cytokine for chronic inflammatory conditions such as in autoimmune
diseases and septic shock. However, a study by Avdiushko et al. showed that macrophages from
mice chronically infected with the LP-BM5 retrovirus, producing a chronic inflammatory condition,
had reduced ability to respond to IL-10. They demonstrated IL-10 production was elevated and
that the elevated expression of IL-10 was caused by the decrease in the responsiveness of
macrophages to IL-10. This hypo-responsiveness was not caused by changes in the expression
of the IL-10 receptor, suggesting regulation at the signaling level (37).

This could have

implications in using IL-10 as a therapeutic tool, because regardless of the amount of IL-10 given,
hypo-responsiveness of IL-10 receptors during chronic inflammation would result in failure of IL10 to have anti-inflammatory effects or to reduce the pro-inflammatory cytokine effects.
Macrophages and monocytes express the IL-10 receptor, which is a member of the Class
11 cytokine receptor family, also known as IFN-receptor family. It is a tetramer consisting of two IL10R1 polypeptide chains and two IL-10R2 chains. Both IL10-R1 and 1L10-R2 belong to the IFNreceptor family (5, 35). The IL-10R1 subunit is constitutively associated with JAK1 and is mainly
involved in downstream signaling. Once the IL-10 receptor is engaged (see figure 5), IL-10R2
acts as an accessory subunit that recruits the second kinase, tyrosine kinase 2 (Tyk2), to the
receptor complex. Upon binding of IL-10 to the IL-1 OR subunits, the JAKs are activated by
transphosphorylation. The activated JAKs then phosphorylate IL-10R1, creating docking sites for
STAT transcription factors such as STAT-3. The intracellular part of the IL-10R1 contains two
tyrosine motifs. Each of the single motifs is sufficient for full STAT-3 activation. STAT-3 becomes
activated at the receptor through tyrosine phosphorylation by JAK, then forms dimers and
subsequently translocates into the nucleus to induce STAT-3 target genes (35, 48, 49).
Even though IL-10 and IL-6 have similar signaling pathways, both have distinct systemic
effects. The anti-inflammatory activity of IL-6 is relatively weaker than that of IL-10. This
difference can be attributed to Suppressor of Cytokine Signaling-3 (S0CS3), the major feedback
inhibitor of

Jak/STAT signaling. IL-6 signal transduction is more sensitive to S0CS3 because

SOCS3 is recruited to one of the five phosphorylated tyrosine residues in the signal transducer
gp130 subunit.

S0CS3 does not interact with phosphorylated tyrosine motifs of the IL-1 OR.
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Studies by Riley et al. have also demonstated a carboxyl-terminal 30-amino acid sequence in the
intracellular domain of the IL-10 receptor not shared by IL-6 which is responsible for the
additional anti-inflammarory function of IL-10 in addition to the STAT-3 pathway (48).
STAT-3 mediates cellular responses but the mechanisms underlying the diverse effects
of this signaling molecule remain unknown. However BATF is likely to be a direct transcriptional
target of STAT-3 because BATF transcription is dependent on the activation of the JAK/STAT-3
signaling pathway (34). It has been shown that STAT-3 is a transcription factor mediating the anti
inflammatory properties of IL-10 (43). However, we do not know if the anti-inflammatory effects
are mediated through the induction of BATF expression.
OBJECTIVES AND GOAL:
We would propose very simply that the possible outcome in response to pathogens
encountered by the macrophage would entail an inflammatory response followed by the
resolution of inflammation. In this model, during the inflammatory response, we would expect Fos
expression to be induced and its activity transiently increase to reach a threshold level for the
inflammatory response. BATF expression would also be induced at the same time as Fos is
induced, however BATF activity would slowly rise during this inflammatory phase. Most dimers
formed during this phase will be Fos/Jun, as Fos competes with BATF for binding to Jun. In turn,
gene expression controlled by AP-1 promoters will increase during the time that Fos expression is
high.
As the pathogen is cleared, we would expect BATF to reach a threshold level for an anti
inflammatory response above the expression of Fos. Fos expression would begin to decline. This
then allows BATF to form dimers with Jun to take over and turn off gene expression. This would
contribute to the resolution of inflammation.

The outcome occuring at a given timepoint would

depend on the type of signal conferred on the macrophage. Even though we expect coexpression
of Fos and BATF, the dominant transcription factor would determine the type of response
obtained. We would therefore expect known inflammatory triggers such as LPS to result in
increased Fos production, whereas anti-inflammatory triggers such as IL-10 to result in increased
BATF production (see figure 6).
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The goal of this research is to test the above mentioned simple model using the M1 cell
line, to demonstrate that pro-inflammatory and anti- inflammatory stimuli have opposing effects on
BATF and Fos expression.

Since Fos/Jun and BATF/Jun can bind to the same motif in the

promoter sequence (i.e. TGACTCA), we would predict that the response is determined by the
dominant dimers formed. For example in the macrophage response to LPS, LPS is a proinflammatory mediator. Therefore we would expect Fos to dominate while LPS is present. BATF
would then only dominate once Fos is degraded. Therefore we would predict that proinflammatory agents would cause a relative reduction in BATF in the cell. Thus we can map out a
time course of Fos and BATF expression in M1 cells in response to different inflammatory
mediators.
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CHAPTER 2
TRANSCRIPTIONAL REGULATION OF M1 CELLS IN
RESPONSE TO IL-6, IL10 AND LPS
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CHAPTER 2.1
INTRODUCTION
AP-1 consists of several distinct homodimers or heterodimers composed of various
members of the Fos, Jun and AT F basic leucine zipper (bZip) family. Members of the leucine
zipper family include c-Jun, JunB, JunD, c-Fos, Fos-B, Fra-1, Fra-2, ATF-2, ATF-a, BATF and
ATF-3 (24, 26). “Leucine zipper” refers to the formation of an alpha helix that contains a leucine
every seven amino acids. These leucines are positioned so that they align on the same side of
the helix and facilitate the formation of dimers through hydrophobic interactions with other family
members. Leucine zipper proteins also contain a basic region which has the binding site for DNA.
In the case of AP-1 family members, dimerization must occur prior to DNA binding. Through
dimerization, the DNA binding regions on the bZip proteins are positioned so as to be in the right
conformation to bind the promoter site on the DNA (11, 24, 26, 27).
The bZip dimers were originally classified into four different sub-classes based on the
promoter elements to which these bZip dimers would bind. The classes were AP-1, ATF/CREB,
C/EBP and Maf. The AP-1 dimer subclass includes Jun/Jun, Fos/Jun and Jun/Fra dimers. These
dimers bind to 5 -TGAGTCA-3', the TP A ” (PMA)-responsive element (TRE). The ATF/CREB
bZip members included CREB, ATF1, ATF2, ATFa, CREBP-2, ATF3, ATF4 and ATF6.

The

dimers of the ATF/CREB family bind to the cyclic AMP-responsive element (CRE) 5 -TGA CG
TCA-3' (24,26,27,28). The only difference between the CRE and TRE site is an additional
cytosine nucleotide in the CRE which is not in the TRE site (26). However, the distinction
between AP-1 and ATF/CREB based on the promoter binding site did not apply in all instances
because AP-1 dimers were sometimes capable of binding to the CRE site as well. AP-1 is now a
more generic term for the dimers of the Fos, Jun and ATF basic leucine zipper family (26). The
known dimers include Jun/Jun, Jun/Fra-1, BATF/Jun, c-Fos/c-Jun, JunB /c-Fos, JunB/FosB, cJun/ATF2 and ATF2/ATF2. Multiple bZip proteins can be expressed at the same time in the cell
(26, 27). Expression of multiple bZip proteins at the same time implies that different AP-1 dimers
are available at about the same time to bind to the DNA. The big question then becomes which of
the AP-1 dimers present at a given time will bind to the TRE sites in the DNA. Could it be a

19

competitive relationship based on the relative concentration of the different dimers, or is it based
on the affinities of the dimers for the TRE site? Alternatively it could be a temporal kind of
relationship, whereby different dimers bind sequentially, or there could be unique targets for the
different dimers. In addition, depending on the composition of the AP-1 dimer that binds to a
target promoter, the resultant effect could be either the activation or inhibition of gene expression.
The possibility of multiple combinations of AP-1 dimerization partners increases the potential for
AP-1 binding to various DNA promoter sites and allows fine-tuning of gene expression in
response to various stimuli.
The Jun and Fos family proteins are found in many different cell types (29). These
proteins function in the regulation of cell proliferation, transformation, differentiation and apoptosis
(26, 27, 29). About ten years ago, another bZip protein, BATF, was identified (45). However the
specific function of BATF in cell regulation is still not totally clear. BATF was first isolated from a
cDNA library prepared from Epstein Barr virus (EBV)-infected human B cells (30). The highest
levels of BATF expression were experimentally detected in an EBV-positive human B-cell line
known as Raji, which is a cell line derived from Burkitt’s lymphoma. EBV-negative human B cells
did not express BATF until infected with biologically active EBV. Studies by Taparowsky et al.,
demonstrated that within 24 hours of infecting human B cells with EBV, BATF mRNA was
induced 25-fold. This suggests that the induction of BATF mRNA and protein is an early cellular
response to the virus. Up-regulation of the expression of BATF in cells infected with EBV
suggests that this virus may have an effect on cellular gene expression patterns through the
increase in BATF (30, 32).

BATF maintains the latency of the virus and the longevity of the

infected cell.
Studies by Senga et al., using M l mouse myeloid leukemia cells, showed that BATF is
up-regulated as an early response to IL-6 or LIF stimulation. Following the stimulation, STAT3 is
activated by phosphorylation and an increase in BATF is subsequently detected. Cell growth was
arrested in the M l cells and these cells differentiated into macrophages as a result of the
stimulation. These results suggest that the STAT3 pathway may modulate AP-1 activity by the
induction of BATF in M l cells (34).
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Analysis of a variety of human tissues and cell lines revealed almost exclusive
expression of BATF mRNA in tissues of hematopoietic origin. The highest tissue expression was
in the lungs (31,32). Considering that BATF is primarily expressed in cells of the hematopoietic
system, we can deduce that the expression in lung tissue is most likely from alveolar
macrophages, although this has not been directly demonstrated. BATF has been shown to be
constitutively expressed in T lymphocytes and inducible expression was demonstrated in B
lymphocytes.
Echlin et al. demonstrated that Jun/Fos dimers activated transcription from the 3xTRELux reporter gene (AP-1 reporter gene) whereas BATF/Jun dimers inhibited activity of the same
gene. Other experiments in fibroblasts also demonstrated that in the presence of the growth
promoting effects of H-Ras or v-Fos oncoproteins, BATF reduced the cellular growth rate when
compared to controls (26).These studies indicated that BATF may function as a negative
regulator of AP-1. This led to our interest in the role of BATF in the function of macrophages as
key coordinators of innate immunity. We thought it would be significant to explore the expression
of BATF after stimulation of M l cells with inflammatory stimuli. Could BATF function to inhibit the
inflammatory response and thus be important in down regulating adverse inflammatory
conditions?
It has been shown that both Fos family members and BATF are able to form dimers with
members of the Jun transcription factor family and that once these dimers have been formed,
they have the same binding affinity for the AP-1 promoter sites in the DNA (31). Our study is
therefore the first step to check the timeline of when Fos family members or BATF are available
to bind to Jun. Depending on the composition of the majority of the dimers that binds to a target
promoter, the resultant effect could be either the activation or inhibition of gene expression.
We used M l cells for continuity with previous experiments demonstrating the induction of
BATF in response to IL-6/LIF stimulation of these cells. Although M l cells do not express c-Fos
(50), they do express Fra-1, which is also a member of the Fos family. Fra-1 dimerizes with Jun
and the Fra/Jun dimer binding specificity to the TRE site is the same as that of the Fos/Jun dimer.
Fra-1 has been shown to exhibit functional equivalence to Fos in the induction of differentiation
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(51). We therefore analyzed BATF expression in comparison to Fra-1 expression when M l ceiis
were stimulated with known inflammatory triggers to determine whether either of these
transcription factors were dominantly expressed to regulate gene expression through the target
promoter.
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CHAPTER 2.2
MATERIALS AND METHODS
CELL CULTURE
The M1 mouse myeloid leukemia cell line was used as a monocyte/macrophage model
(American Type Culture Collection, Manassas, VA, USA). Cells were maintained in RPMI 1640
(Roswell Park Memorial Institute) medium with 10% (v/v) heat-inactivated fetal bovine serum, and
50pg/ml gentamycin. The cells were Incubated in a humidified, 5% carbon dioxide incubator at
37°C.
CELL STIMULATION
Cells were stimulated at 37°C with IL-10 or IL-6 from R&D Systems (Minneapolis, MN). The cell
stimulation was conducted in 1ml cultures at a concentration of 5x10® cells/ml. The indicated
mediators (i.e. LPS at lOpg/ml, IL-6 at SOng/ml and IL-10 at lOng/ml) were added at the time
points indicated. Following the stimulation, the cells were harvested and prepared for assays to
detect the presence of Fos, BATF, STATS and pSTATS.
SAMPLE PREPARATION
After stimulation, each sample was transferred to a microfuge tube and centrifuged to pellet the
cells (1200 rpm, 5 minutes). The cells were washed once in serum-free RPMI 1640 and then
lysed by addition of RIPA buffer (with 1 pg/ml each of aprotinin and leupeptin) for 15 minutes on
ice. Samples were then centrifuged (10,000 rpm, 5 minutes, 4°C) to remove the insoluble debris.
The supernatant, representing the cell lysate, was collected and transferred to a new tube. An
equal volume of sample buffer containing 2-mercaptoethanol was added and the samples were
heated for 10 minutes at 95°C to reduce and denature the proteins.
GEL ELECTROPHORESIS AND PROTEIN TRANSFER
A 10% SDS-PAGE gel was used to separate the sample proteins by size. The proteins were
then transferred to a polyvinylidene diflouride (PVDF) membrane for detection of BATF, Fos,
STATS and pSTATS by Western blot.
The transfer buffer used consisted of 25mM Tris, 192mM glycine and 20% (vol/vol) methanol.
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WESTERN BLOT
The PVDF membrane was incubated with a blocking buffer consisting of 5% powdered
milk in Tris buffered saline (0.05M Tris and 0.85% NaCI), pH 7.4 with 0.05%Tween, (TBST) for 30
minutes.
BATF detection:
BATF antiserum (kindly provided by E.J. Taparowsky, Purdue University, 1:1000 dilution) was
added in the presence of blocking buffer for the detection of BATF and allowed to incubate, with
rocking, for 2 hours at room temperature. The membrane was then washed with TBST for 30
minutes, changing the buffer every 5 minutes. After the last wash, the membrane was incubated
for one hour with the detection antibody conjugate, goat anti-rabbit IgG-HRP (1:10000 dilution in
5% miik-TBST). The membrane was washed as before and then ECL reagent (Pierce, USA) was
added to the membrane according to the manufacturer’s instructions. The membrane, wrapped in
Saran Wrap, was exposed to film overnight.
Fra-1 detection:
The detection of Fra-1 followed a similar procedure to BATF except that the Fos antibody was
directly conjugated to HRP for detection. This antibody detects c-Fos, FosB, Fra-1 and Fra-2,
which are ail Fos family members.

Fos antibody, (K-25,

1:1000 dilution, Santa Cruz

Biotechnology, USA) was added to the blocked membrane for 2 hours, washed, then reacted with
ECL reagent and exposed to film overnight.
STAT3 detection:
For detection of STAT3, the PVDF membrane was incubated with blocking buffer (5% powdered
milk in TBST) for 30 minutes. STAT3 antibody (F-2,1:500 dilution, Santa Cruz) was then added
and allowed to incubate for 2 hours. The membrane was then washed with TBST for 30 minutes,
changing the buffer every 5 minutes. After the last wash, the membrane was incubated for one
hour with the detection antibody conjugate, goat anti-mouse IgG-HRP (1:10000 dilution in 5%
miik-TBST). The membrane was washed and developed as described above.
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pSTATS detection:
The detection of pSTATS followed a similar procedure except that the pSTATS mouse antibody
(B-7) was used (1:500 dilution Santa Cruz Biotechnology, USA).
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CHAPTER 2.3
RESULTS

See table 3 for results showing the expression of Fra-1, BATF, STATS AND pSTATS after
stimulation with LPS, IL-6 and IL-10.
Results showed that Fra-1 was constitutively expressed by the M l cells and, after
stimulation with LPS, there was an increase in Fra-1 at four hours of stimulation (Fig 7A). BATF
was also constitutively expressed but remained constant throughout the four hours of stimulation
(Fig 7B).
Considering that LPS has been shown to lead to the direct production of IL-6, it was
important to determine whether these effects in Fra-1 and BATF were due directly from LPS
acting on the M l cells or indirectly from LPS inducing IL-6 production which in turn acted on the
M l cells. IL-6 is produced by macrophages, monocytes, fibroblasts, and endothelial cells (1, 5,10)
and has been shown to induce the terminal differentiation of M l myeloid leukemia cells to
macrophages (52). We decided to look at IL-6 directly because it is known to activate STATS, a
transcription factor known to induce BATF expression.
The level of expression of STATS and pSTATS was examined during the same time
frames that as those for the detection of the expression of BATF and Fos since both IL-6 and IL10 signal through the STATS pathway. Detection of pSTATS, which is the phosphorylated form of
STATS, would give an indication of the time frame in which STATS is activated and would verify
successful stimulation through the cytokine receptors.
After stimulation of M l cells directly with IL6, results showed that pSTATS expression
was constant throughout the four hours of stimulation (Fig 8C) and total STATS expression
increased (Fig 8D). Fra-1 was constitutively expressed by the M l cells and increased over time
after stimulation (Fig 8A). BATF was also constitutively expressed and there was a slight
decrease in BATF following stimulation (Fig 8B).
IL-10 provides a major anti-inflammatory signal which down regulates the effects of the
inflammatory cytokines. Results from the western blots after the four hour stimulation with IL10
showed that there was no pSTATS detected (Fig 9C). This outcome was not expected because
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the lack of pSTATS means that the STATS pathway was not activated. Contrary to the results
obtained after IL-6 stimulation, which showed constitutive expression of pSTATS, IL-10 showed
no constitutive expression. However it was interesting to note that Fra-1 expression decreased
(Fig 9A) BATF expression increased (Fig 98) and STATS expression increased (Fig 9D) even
though we had no pSTATS expression.
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CHAPTER 2.4
DISCUSSION
The ability to respond to extracellular signals such as cytokines is an important and integral part
of the immune response. These extracellular signals result in the modulation of transcription
factor activity via signal transduction pathways (6, 10). The transcription factor AP-1 consists of
homodimers and heterodimers of bZip proteins such as Fos, Jun, ATF and BATF, which are
capable of binding onto the TRE site of various promoters to activate the associated gene
transcription (24). Regulation of gene expression is not mediated solely by a particular set of
transcription factors but rather may involve many combinations of transcription factors. We
determined the level of expression of BATF in comparison to Fos expression when M l cells were
stimulated with the inflammatory mediators IL-6, LPS and IL-10. The promoters of many
inflammatory cytokine genes contain AP-1 binding sites (54), suggesting a role for AP-1 during
inflammation.
Fos/Jun dimer complexes also function in gene regulation of a number of functions in
the cell such as cell growth and development (27, 28, 29, 31, 53). The BATF/Jun dimer has been
shown to negatively regulate/inhibit functions in the cell (26, 30, 31, 33). However the function of
BATF during inflammation remains largely unclear. We therefore analyzed the level of BATF
expression in comparison to Fos expression because both these bZip proteins are capable of
dimerizing with Jun. Once these dimers are formed, only then can the binding to the TRE DNA
binding site occur and thus gene regulation can occur (11, 24, 26, 27, 53). It has been shown that
Fos/Jun dimers have the same affinity of binding to the TRE site as BATF/Jun dimers (26,31).
Therefore from the experiments we performed and the above information, it would be reasonable
to assume that the concentration of Fos in relation to BATF is a major determinant as to which of
the two dimers will bind to the TRE site and thus regulate expression of the associated gene. It
was observed that throughout the 4 hour periods, neither BATF nor Fos disappeared completely
but were instead coexpressed. However one of the two bZip proteins was upregulated and the
other downregulated or remained constant (Fig 7A, 7B, BA, 8B, 9A, 9B). Therefore the balance
between Fos and BATF determined what kind of response persisted. If BATF indeed acts as a
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negative regulator of inflammation, the results would be consistent with research done by P.
Ward (55) where he inferred that pro-inflammatory and anti-inflammatory mediators are
generated at the same time. The balance between these two classes of mediators determines
whether the inflammatory response persists and intensifies or whether it is contained. In other
words, both types of mediators could be expressed at the same time. However, the relative level
of expression of each mediator is what determines the type of response.
From the results shown, BATF expression remained constant when M1 cells were
stimulated with LPS (Fig. 78), whereas Fra-1 expression (Fig. 7A) increased. This suggests that
with regards to Fos and BATF, Fos is the more dominant transcription factor in response to LPS.
The most likely explanation of the results would be that LPS induced the MAP kinase pathway
and it also induced the activation of the NFkB pathway (Fig. 5). TPA uses the MAP kinase
pathway to upregulate both Fos and Jun (56). Considering that LPS activates the same pathway
as TPA, we would expect that LPS also increases Fos expression via the MAP kinase pathway.
The MAPK pathway also results in the activation of JUN kinase which in turn phosphorylates Jun.
The phosphorylation of Jun has been linked with induction of transcriptional activity.
NF kB has been shown to physically interact with Fos/Jun, lending synergy to the
induction of the inflammatory response. Experiments by Lui et al. (57) showed that BATF is
induced following direct NF kB activation. From our results we observed that BATF was present
even though Fos was the dominant of the two transcription factors. The presence of BATF
probably helps limit the extent to which inflammation is occurring. These results fit our proposed
model for a hypothetical inflammatory response dependent on Fos and BATF.
When M l cells were stimulated with IL-6, there was an increase in Fra-1 expression (Fig.
8A) and there was a decrease in BATF following stimulation (Fig. 8B). Contrary to the results by
Senga et al. (34), in which BATF expression was induced following stimulation with IL-6, our
results show that we had constitutive expression of BATF. This discrepancy in results may be due
to different cell culture conditions. We used cells that had adhered to the flask during culture and
it is possible that these monocytes could have already differentiated into macrophages during
routine culture. Macrophages are capable of making IL-6 during culture, in turn the presence of
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IL-6 leads to cell differentiation of the myeloid leukemic cell line, M1, to macrophages (50, 52).
The constitutive expression of BATF could therefore be due to the fact that the stimulation was
actually done on a mixed cell population of monocytes and macrophages rather than solely on
monocytes.
The fact that following IL-6 stimulation, Fra-1 expression increased whereas BATF
expression decreased, suggests that with regards to Fos and BATF, Fos is the more dominant
transcription factor in response to IL-6. IL-6 is known to activate the MAPK pathway via the SHP2
domain (Fig 4) (58). This would in turn give rise to an increase in Fos expression. Our results also
show that the STATS pathway was activated due to the presence of pSTATS whose expression
remained constant whereas the total STATS expression increased. Increase in total STATS
expression is most likely an indication of the continued activation of the pathway.
Following stimulation of the M l cells with the key anti-inflammatory cytokine, IL-10, there
was a decrease in Fra-1 expression (Fig 9A) and an increase in BATF expression (Fig 9B).
However one unexpected outcome of the experiments was that there was no expression of
pSTATS (Fig 9C) as a result of the stimulation. The lack of pSTATS indicates that the STATS
pathway was not activated following stimulation of the M l cells with IL-10. One likely reason for
the discrepancy would be that the M l cell line may lack IL-10 receptors Most monocyte cell lines
do have IL-10 receptors; however their presence on M l cells is unknown. Another possible
explanation could be that the STATS pathway may be inhibited at some point in the signaling
pathway. This would have most likely involved inhibition of phosphorylation of STATS by blocking
signaling upstream of this event (see fig 5). For example, inhibition of tyrosine kinase (Tyk) could
lead to inhibition of STATS activation.
Looking at our proposed model (fig 6) and the results we obtained, we could conclude the
results from our experiments loosely fit the model. This model is naïve in comparison to the
complexity of the transcriptional regulation of the inflammatory response during inflammation.
There are many variables with respect to the possibility of signaling pathway crosstalk as well as
gene regulation.
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Following all the experiments to determine the role of BATF in the inflammatory
response, we realized that changes need to be made in some aspects of the experiments. One
important change would be the use of a cell line whose exact stage of differentiation is known.
During our experiments, the cell line was probably a mixed cell population in terms of the various
stages of differentiation. Over time, some cells began to adhere to the cell culture flask while
others remained nonadherant and we used both for the experiments. Some cells were most likely
mature macrophages (those adhering to the flask), whereas other cells were just newly divided
Ml cells. It would be helpful to stain the cells with antibodies to monocyte or macrophage
differentiation markers to determine the differentiation state of the cell population. Knowing the
specific receptors expressed would clarify the probable pathways that could be activated and thus
shed some light on interactions that are likely occurring.
In addition, use of inhibitors to specific pathways would help sort out which pathways are
being activated in response to a specific stimulus. For example, to find out if LPS is activating the
MARK pathway directly or indirectly through the induction of IL-6, an SHP2 inhibitor could be
used to block the pathway used by IL-6. If the MAPK pathway is still activated, one can then infer
that LPS is directly activating that pathway. We could also check to see if IL-6 is being made in
culture by measuring IL-6 in the media following routine culture. This would give us insight as to
whether IL-6 could have caused differentiation of the monocytes into macrophages. The use of
primary macrophages or monocytes could help reflect what actually goes on physiologically in
vivo as opposed to using M1 cells which are a myeloid leukemia cell line. These M1 cells lack cFos but have Fra-1 whereas primary cells express c-Fos. There is also a possibility that the IL-10
receptors were hyporesponsive In the myeloid leukemia cells. In neutrophils, it has been shown
that their capacity to respond to IL-10 is dependent on the level of expression of the IL-10
receptor (59,60).
Once the time course of transcription factor expression is fully described, a second stage
of the research would be to measure transcription factor binding to an AP-1 consensus DNA
sequence. This would give more conclusive evidence as to which of the two dimers (BATF/Jun
or Fos/Jun) is actually binding and thus giving rise to the control of the TRE site foilowing the
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stimulations. This could be done by use of the electrophoretic mobility shift assays (EMSA). To
investigate the DNA binding preference of BATF/Jun compared to Fos/Jun complexes, to the
TRE SITE, radiolabeled AP-1 (TRE) oligonucleotides would be used. Following the stimulations,
nuclear extracts could be used to generate protein/DNA complexes that can then be resolved by
electrophoresis through polyacrylamide gels and visualized by autoradiography.
This would give more conclusive data as to whether BATF/Jun or Fos/Jun dimers
actually compete for the same binding site or have different target sites altogether. In summation,
the groundwork to finding the transcriptional regulation of the macrophage response in
inflammation has been initiated.
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TABLES

CYTOKINE
Macrophage Migration Inhibitory Factor (MIF)
Macrophage Activating Factor (MAF),
Leukemia Inhibitory Factor (LIF)
Macrophage Fusion Factor (MFF),

Interleukin 2 (IL-2)
Interleukin 3 (IL-3)
Interleukin
Interleukin
Interleukin
Interleukin
Interleukin
Interleukin

4 (IL-4)
6 (IL-6)
10 (IL-10)
13 (IL-13)
16 (IL-16)
17 (IL-17)

Tumor Necrosis Factor alpha (TNF-a)
Tumor Necrosis Factor beta (TNF-3)
Interferon gamma (IFN- y)

Granulocyte-Macrophage Colony Stimulating
Factor (GM-CSF)
Monocyte Colony Stimulating Factor (M-CSF)
Colony Stimulating Factor 1 (CSF-1)

FUNCTION
Activates macrophages and inhibits their
migration
Affects activation, growth and differentiation of
macrophages
Promotes differentiation of monocytes to
macrophages
Induces the fusion of bone marrow cells and
alveolar macrophages to large multinucleated
cells that produce high levels of IL-1.
Stimulates cell growth and development
Growth factor for hematopoietic cells stimulates
colony formation
Promotes cell growth and development
Pro-Inflammatory
Anti-inflammatory
Suppresses inflammatory responses
Stimulates migration of cells
Enhances expression of ICAM-1, thus making
cells more adhesive
Strong mediator of inflammatory and immune
functions
Regulates cell growth and differentiation
Affects activation, growth and differentiation of
cells. Upregulates MHC expression on antigen
presenting cells.
Differentiation factor for granulocytic and
monocytic cell lineages.
Essential for growth and differentiation of
monocytes.
Essential for cell growth and differentiation

Table 1: Cytokines for which macrophages have receptors and the functions o f the
cytokines (1, 5, 10)
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Enzymes

-Lysozyme
-Lysosomal acid hydrolases
•
Lipases
•
Proteases
•
(Deoxy)ribonuclease
•
Phosphatases
•
Glycosidases
•
Sulfatases

Complement Components

-Classical pathway
• C1,C4,C2,C3,C5
-Alternative pathway
factor B, factor D, properdin

Reactive Oxygen Intermediates

-Superoxide
-Hydrogen peroxide
-Hydroxyl radical
-Nitric oxide
-Peroxynitrite
-IL-1,IL-6,IL-10.IL-12, IL-15, IL-18
-TNF-a
-Interferons-a and y
-Platelet-derived growth factors
-Fibroblast growth factor
-Transforming growth factor-(3
-GM-CSF
-Erythropoietin
-Factor inducing monocytopoiesis
-Angiogenesis factor
-CXC chemokines (IL-8, GRO, ENA-78, IL-10)

Cytokines

Table 2. Macrophage Secretory Products (1, 5,10)
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LPS

IL-6

IL-10

Fra-1

Increased

Increased

Decreased

BATF

Constant

Decreased

Increased

STAT3

Not Done

Increased

Increased

pSTAT3

Not Done

Constant

No results

Table 3: Results showing the expression o f Fra-1, BATF, STATS AND pSTAT3 after
stimulation with LPS, IL-6 and IL-10.
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FIGURES

Figure 1: The structure o f the classical AP-1/DNA complex. AP-1 is a dimer formed by Jun
and its non-homologous protein Fos. It contains a ieucine zipper motif where two alpha heiices
look like a zipper with leucine residues iining up on the inside o f the zipper. The leucine-zippercontaining transcription factor binds DNA as a dimer (25)
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Figure 2: Proposed relationship between Fos/Jun (AP-1) and BATF/Jun in gene
regulation in the macrophage.
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Cone
FOS
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Time

Figure 6: Simple model to demonstrate proposed timeline o f expression o f Fos relative to
BATF during an inflammatory response. Grey indicates Fos/Jun activity; gene transcription is
promoted resulting in an inflammatory response. White indicates BATF/Jun activity; gene
transcription is suppressed resulting in the resolution o f inflammation.
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Figure 7: Stimulation ofM 1 ceils with LPS. M1 cells were stimulated with LPS (10pg/ml) for
0-4 hours and harvested. Whole cell lysates were used for the detection o f Fra-1 (A), BATF (B).
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Figure 8: Stimulation ofM 1 cells with IL-6. M1 cells were stimulated with IL6 (50ng/ml) for 0-4
hours and harvested. Whole cell lysates were used for the detection o f Fra-1 (A), BATF (B),
STAT3 (C) and pSTAT3 (D) by Western blot. All experiments were repeated on different days to
ensure reproducibility o f results.
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Figure 9: Stimulation o f M l cells IL-10. M1 cells were stimulated with IL10 (lOng/ml) for 0-4
hours and harvested. Whole cell lysates were used for the detection o f Fra-1 (A), BATF (B),
STAT3 (C) and pSTAT3 (not shown) by Western blot. All experiments were repeated on different
days to ensure reproducibility o f results.
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